The companies anticipate being able to close the acquisition in early Q4 2023
THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 – Amgen and Horizon Therapeutics plc announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen’s acquisition of Horizon.
As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly seek the final approvals required under Irish law to close the acquisition.
Amgen has consistently stated to the FTC, the courts and the public that it has no reason, ability or intention to bundle Horizon’s TEPEZZA® (teprotumumab-trbw) or KRYSTEXXA® (pegloticase injection) with any of its products. This narrow assurance, formalized in the consent order with the FTC, will have no impact on Amgen’s business.
The companies anticipate being able to close the acquisition in early fourth-quarter 2023 and look forward to the opportunity to serve patients around the world suffering from rare diseases.
About Horizon Therapeutics
Founded in 2008, Horizon Therapeutics is a focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Horizon is headquartered in Dublin, Ireland, with global offices including one in Rockville, Md. Learn more at https://www.horizontherapeutics.com/
A biotechnology pioneer since 1980, Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is part of the Nasdaq-100 index. Learn more about Amgen at https://www.amgen.com/